Business Wire

EGON-ZEHNDER

28.5.2019 07:02:25 CEST | Business Wire | Press release

Share
Egon Zehnder and Sinequanon (SQN) Formalize Business Partnership to Scale SQN’s Revolutionary, AI-enabled Approach to Culture Transformation Through the Harnessing of Human Potential

Egon Zehnder, the world’s leadership consulting firm, has formalized an agreement to purchase a minority stake in Zurich, Switzerland-based Sinequanon (SQN), a firm that uses AI and advanced analytics to improve workplace culture and performance. SQN is the first to have cracked the code linking culture to performance consistently over time and in every client engagement.

The investment in SQN signals Egon Zehnder’s intent to build on its 55 years of experience shaping leadership and culture through SQN’s unique combination of advanced technology and a human approach to leadership. The companies will work together to disseminate SQN’s Living Analytics™ platform and Flow Operating System™.

SQN’s flowOS™ uses a data-driven and AI-enabled process to identify an organization’s optimal culture and then drives the behavioral change needed by individuals, teams and business units. In its work with clients, flowOS™ has consistently delivered significant improvements in people energy and productivity.

“We hear consistently from clients that culture change is one of the most challenging aspects of leadership. In SQN we have found an innovative partner to deliver integrated services to our clients by marrying both human leadership insights and pioneering technology,” said Jill Ader, Chairwoman, Egon Zehnder. “We strongly believe the best consulting services we can offer our clients combine technology and humanity,” she added.

The partnership is founded on the shared belief that culture change is critical to helping organizations adapt to and thrive in today’s complex world. It combines Egon Zehnder’s expertise advising and unlocking the potential of senior leaders with SQN’s ability to assess and accelerate the power of the full organization through cultural change.

“It has always frustrated me that large organizations trap massive amounts of human energy. In fact, our data shows that less than 10% of employees operate at their full potential. Now as organizations are feeling the brutal effect of disruption, an extraordinary win-win opportunity between employees and businesses is emerging. My life’s mission is to find a business-minded method to enable this – and that is flowOS™,” said Per Lagerstrom, Chief Executive Officer, SQN. “Egon Zehnder and SQN share a core mission to unlock human potential. I believe we can make magic together, and am excited to be partnering with them,” he added.

“We believe the world needs more great leaders. In fact, recent research we conducted with 402 CEOs revealed they find culture change one of the most challenging aspects of the role,” noted Gabriel Andrade, Partner, Egon Zehnder and Board member, SQN. “With SQN, the intelligence of the end-to-end operating system and guided support we can provide clients can change human resources and performance management for the foreseeable future.”

SQN brings new capabilities to an already powerful set of partnerships. Egon Zehnder’s strategic alliance with Mobius Executive Leadership, the London and Cambridge, MA-based leadership development firm, delivers customized executive development programs at the CEO and executive levels that enable breakthroughs often described by participants as “life changing,” which in turn can serve as a multiplier to the impact of SQN. In addition, Egon Zehnder has partnered with Paradox Strategies, the consulting firm co-founded by Harvard University Professor Linda Hill, to develop the Innovation Quotient (IQ), a proprietary culture diagnostic based on Hill’s research that helps clients better understand the degree to which their cultures enable – or inhibit – their ability to innovate.

Notes to Editors

Sinequanon (SQN) is a privately held PeopleTech start-up founded in 2015. While we work globally and across industries, our home is in Switzerland with operations in South Africa and the Czech Republic.

SQN has a passionate team of 60, unified by a fundamental belief in our ability as humans to radically change and grow and a hunger to marry the soft skills with the hard. Our people work across behavioral, neural and data science, technology and client services.

At SQN, we believe that human capital management and change consulting are ripe for disruption. We have combined data, science and sound business principles into a ground breaking approach that taps into the well of human energy, so often trapped in large businesses, delivering material improvements to both the employee experience and the company’s bottom line.

We offer a suite of culture change products and services under the Living Analytics™ and flowOS™ brands, coupled with a disruptive tech enabled client delivery model.

http://sqn.world

About Egon Zehnder

Egon Zehnder is the world’s leadership consulting firm, sharing one goal: to transform people, organizations and the world through great leadership.

We know what great leaders can do and are passionate about delivering the best leadership solutions for our clients.

As One Firm, our more than 480 Consultants in 68 offices and 40 countries bring our individual strengths to form one powerful collaborative team.

We partner closely with public and private corporations, family-owned enterprises, and non-profit and government agencies to provide Board advisory services, CEO search and succession, executive search, executive assessment, leadership development and organizational transformation.

We offer a range of integrated services to support our leadership consulting work: Our strategic alliance with Mobius Executive Leadership, the London and Cambridge, MA based leadership development firm, delivers customized executive development programs at the CEO and executive levels that enable breakthroughs often described by participants as “life changing.” In addition, we have partnered with Paradox Strategies, the consulting firm co-founded by Harvard University Professor Linda Hill, to develop the Innovation Quotient (IQ), a proprietary culture diagnostic based on Hill’s research that helps clients better understand the degree to which their cultures enable – or inhibit – their ability to innovate.

We share a commitment and pride in doing work that contributes to successful careers, stronger companies and a better world.

www.egonzehnder.com

Contact:

Global media Hilary Crnkovich Global Head of Marketing and Communications P: +1 312-260-8978

Stacy Drumtra US Head of Marketing and Communications P: +1 312-260-8974

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye